Amphastar Pharmaceuticals, Inc.
11570 6th Street
Rancho Cucamonga
California
91730
United States
Tel: 800-423-4136
Fax: 909-980-8296
Website: http://www.amphastar.com/
Email: info@amphastar.com
129 articles about Amphastar Pharmaceuticals, Inc.
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
2/28/2024
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2023.
-
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
2/20/2024
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
-
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST.
-
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
11/20/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST.
-
Amphastar Pharmaceuticals to Present at the 2023 Jefferies London Healthcare Conference
11/9/2023
Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT.
-
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
11/1/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
-
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
9/13/2023
Amphastar Pharmaceuticals, Inc. announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
9/11/2023
Amphastar Pharmaceuticals, Inc. announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
8/31/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time.
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
8/8/2023
Amphastar Pharmaceuticals, Inc. reported results for the three months ended June 30, 2023.
-
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
8/2/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
-
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
6/30/2023
Amphastar Pharmaceuticals, Inc. announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company .
-
Amphastar Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
5/31/2023
Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time.
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
5/9/2023
Amphastar Pharmaceuticals, Inc. reported results for the three months ended March 31, 2023.
-
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
5/3/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
-
Lilly to Divest BAQSIMI to Amphastar
4/24/2023
Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
-
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
4/24/2023
Amphastar Pharmaceuticals, Inc. announced that the Company will provide a Business update and hold a Conference call , Monday, April 24, 2023, at 6:00 am Pacific Time.
-
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
4/12/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19th, 2023 at 12:45 pm Eastern Time.
-
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
3/8/2023
Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted approval of its New Drug Application for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device.
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022
2/28/2023
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2022.